Treatment of plaque‐type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial

David, Michael; Akerman, Lehavit; Ziv, Michael; Kadurina, Miroslava; Gospodinov, Dimitar; Pavlotsky, Felix; Yankova, Rumyana; Kouzeva, V.; Ramon, Michal; Silverman, Michael H.; Fishman, Pnina

doi:10.1111/j.1468-3083.2011.04078.x

Cited by 86 publications

(72 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, CF101 was tested in a phase II, multicenter, randomized, double-blind, dose-ranging, placebo-controlled trial in patients with moderate to severe chronic plaque-type psoriasis. In this study the drug was found to be safe and well tolerated, and the improvement was progressive and linear throughout the period examined (David et al, 2012). As a consequence, CF101 has entered a phase II/III randomized, doubleblind, placebo-controlled, dose-finding study of the efficacy and safety of daily CF101 administered orally in patients with moderate to severe plaque psoriasis (ClinicalTrials.gov).…”

Section: Immune System and Inflammationmentioning

confidence: 99%

The A₃Adenosine Receptor: History and Perspectives

et al. 2014

View full text Add to dashboard Cite

Section: Immune System and Inflammationmentioning

confidence: 99%

The A₃Adenosine Receptor: History and Perspectives

et al. 2014

View full text Add to dashboard Cite

“…In addition, this receptor subtype could be involved in the murine imiquimod-induced model of psoriasis, because imiquimod has been also characterized as an A 2A AR antagonist (Flutter and Nestle, 2013;Schon et al, 2006). Furthermore, an A 3 AR agonist is currently being evaluated in phase II and III clinical trials in patients with moderate to severe plaque psoriasis because of its regulatory effect on T-cell function (David et al, 2012;Kofoed et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Adenosine A2A and A2B Receptors Differentially Modulate Keratinocyte Proliferation: Possible Deregulation in Psoriatic Epidermis

Andrés

Terencio

Arasa

et al. 2017

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Adenosine is a potent regulator of inflammation and immunity, but the role of adenosine receptors in keratinocytes remains controversial. We determined that in addition to A 2B receptors, human epidermal keratinocytes also express A 2A receptors, although to a lower extent. Through the use of selective adenosine receptor agonists and antagonists, we showed that physiological concentrations of adenosine activate A 2B receptors in normal human keratinocytes, inducing cell cycle arrest through the increase of intracellular calcium but not through cAMP signaling. In contrast, the selective activation of A 2A receptors by CGS-21680 induces keratinocyte proliferation via p38emitogen-activated protein kinase activation. Adenosine and selective A 2A and A 2B agonists presented anti-inflammatory profiles independent of adenosine receptors but mediated by membrane phosphatase activation. Finally, keratinocyte exposure to diverse inflammatory cytokines altered adenosine receptor expression by reducing A 2B and increasing A 2A , a pattern also observed in psoriatic epidermis. Because increased epidermal turnover and inflammatory response are characteristics of psoriatic disease, further studies are needed to assess the role and consequences of the altered adenosine receptor expression in lesional and nonlesional psoriatic keratinocytes.

show abstract

“…A supporting factor for this conclusion comes also from the fact that meloxicam is already in clinical use for other indications. IB-MECA is under clinical studies (for other indications, too) in which it was found to be safe and well tolerated [34][35][36].…”

Section: Discussionmentioning

confidence: 99%

Combined pharmacological therapy of the acute radiation disease using a cyclooxygenase-2 inhibitor and an adenosine A3 receptor agonist

et al. 2014

View full text Add to dashboard Cite

Combined approaches to the treatment of acute radiation disease are preferred to single-agent therapies due to proven or anticipated better outcomes comprising increased therapeutic efficacy and decreased incidence of undesirable side effects. Our studies on post-exposure treatment of mice irradiated by sublethal or lethal doses of ionizing radiation included testing the effectiveness of meloxicam, a cyclooxygenase-2 inhibitor, and IB-MECA, an adenosine A3 receptor agonist. The efficacy of meloxicam and IB-MECA to positively influence the progress of the acute radiation disease has been tested in situations of their combined administration with granulocyte colony-stimulating factor (G-CSF) or with each other. The results of our studies revealed a significantly improved regeneration of hematopoietic cell populations ranging from the bone marrow progenitor cells to mature blood cells following combined treatments. Also, survival of mice exposed to lethal radiation doses was highest in the animals treated with a combination of the two drugs. It can be inferred from the results that if the drug combinations employed were used in humans, e.g. in the treatment of victims of radiation accidents, a better therapeutic outcome could be expected. Therefore, further studies directed at clinical applications of meloxicam and IB-MECA in radiation victims is recommended.

show abstract

Treatment of plaque‐type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial

Abstract: CF101 was well tolerated and demonstrated clear evidence of efficacy in patients with moderate to severe plaque psoriasis.

Cited by 86 publications

References 26 publications

The A₃Adenosine Receptor: History and Perspectives

The A₃Adenosine Receptor: History and Perspectives

Adenosine A2A and A2B Receptors Differentially Modulate Keratinocyte Proliferation: Possible Deregulation in Psoriatic Epidermis

Combined pharmacological therapy of the acute radiation disease using a cyclooxygenase-2 inhibitor and an adenosine A3 receptor agonist

Contact Info

Product

Resources

About

Treatment of plaque‐type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial

Abstract: CF101 was well tolerated and demonstrated clear evidence of efficacy in patients with moderate to severe plaque psoriasis.

Cited by 86 publications

References 26 publications

The A3Adenosine Receptor: History and Perspectives

The A3Adenosine Receptor: History and Perspectives

Adenosine A2A and A2B Receptors Differentially Modulate Keratinocyte Proliferation: Possible Deregulation in Psoriatic Epidermis

Combined pharmacological therapy of the acute radiation disease using a cyclooxygenase-2 inhibitor and an adenosine A3 receptor agonist

Contact Info

Product

Resources

About

The A₃Adenosine Receptor: History and Perspectives

The A₃Adenosine Receptor: History and Perspectives